68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.

Recruiting now · Phase 2

Conditions studied: Clear Cell Renal Cell Carcinoma

In brief

Radiation therapy (RT) is an effective treatment for patients with advanced-stage clear cell renal cell carcinoma (ccRCC). Current evidence has shown promising outcomes combining radiation therapy and standard systemic therapy in patients with metastatic/recurrent ccRCC. CAIX is a highly sensitive and specific biomarker expressed on ccRCC and in previous studies the investigators have shown excellent diagnostic efficacy of 68Ga-NY104, a CAIX-targeted PET tracer, in patients with metastatic ccRCC. In this study, the investigators aim to investigate the effect of 68Ga-NY104, and 18F-FDG PET/CT guided RT combining standard systemic therapy in patients with metastatic ccRCC.

Key facts

Study ID

NCT06613269

Run by

Peking Union Medical College Hospital

People needed

40

Starts

2024-03-27

Expected to finish

2028-09-01

Last updated by the study team

2024-09-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years old
• Histologically or cytologically confirmed clear cell renal cell carcinoma
• Eligible for radiation therapy: no more than 10 lesions in total
• Expected survival: over 3 months
• ECOG: 0 or 1
• Sufficient organ function
• Written informed consent

You may not qualify if…

• Brain metastasis/carcinomatous meningitis
• Other malignant tumors that are not controlled within 5 years, except for non-metastatic low-risk prostate cancer.
• Pregnant or breastfeeding.
• Active infection.

Where it is running

• Peking University First Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.